[ad_1]
Virologists from Pécs revealed more details about the Pfizer / BioNTech vaccine with reference to an article published in The New England Journal of Medicine. A study investigating side effects has been reported on the Virology Pécs Facebook page.
According to experts, a total of 43,548 people enrolled in the clinical trial phase: 21,720 people received the vaccine formulation, while 21,728 people received the placebo formulation. After the first dose of the vaccine has been given, the second dose can be given 21 days later. The study was conducted in people over 16 years of age. The period currently being evaluated is two months, during which the immune response will certainly be effective, but will probably be much longer.
Those skilled in the art will appreciate that some degree of protection has been established 12 days after the first dose. 7 days after the second dose, an efficacy of 95% can be established.
Efficacy ranged from 90 to 100 percent for age groups, gender, ethnicity, BMI index, and other health conditions. This means that there is a good chance that these factors will not affect its effectiveness. The Pécs virologists also wrote in their post that fortunately the side effects are negligible so there is no reason to panic, everyone can safely administer it.
Some redness and swelling was observed at the vaccination site, but only in low percentages, while short-term pain at the vaccination site was described in some subjects. Headache, chills and, in some cases, fever, which resolved without exception, were reported more frequently than with placebo.
They write. They added that the latter complaints were slightly more common in the 16- to 55-year-old age group and were generally more common after the second dose than after the first. Based on these, it can be said that the safety profile is particularly good.
In the United States, nearly 15.8 million people have been identified so far and the number of deaths exceeds 294,000.
[ad_2]
